info@amda-pompe.org

MTAP Fact Sheet June 2007

Jun 27, 2007 | NEWS

MTAP, the Myozyme® (alglucosidase alfa) Temporary Access Program, is a clinical program to provide access to Myozyme produced by a larger scale manufacturing process for a limited time until this manufacturing scale is approved by the FDA.  Patients enrolled in MTAP...

Genzyme Pompe Program Update—June 2007

Jun 27, 2007 | NEWS

Genzyme would like to take this opportunity to provide a brief update to the Pompe patient community regarding the US supply of Myozyme® (alglucosidase alfa).  As planned, Genzyme submitted the necessary documentation to the FDA this month for the licensure of the...

MTAP Fact Sheet May 2007

May 2, 2007 | NEWS

MTAP, the Myozyme® (alglucosidase alfa) Temporary Access Program, is a clinical program to provide access to Myozyme produced by a larger scale manufacturing process for a limited time until this manufacturing scale is approved by the FDA.  Patients enrolled in MTAP...

Genzyme Pompe Program Update—April 2007

Apr 24, 2007 | NEWS

As many of you are aware, a standard part of the biologics drug development process is to incrementally scale-up manufacturing capacity as demand for the product increases. During the development of Myozyme®, Genzyme began the manufacturing process using a smaller...

2006 Conference

Nov 24, 2006 | CONFERENCES

2006 AMDA/IPA Conference Report By Allan Muir With contributions from George Fox and Jared Salbato Friday—November 17, 2006 Texas Hoe Down at Sea World Report by George Fox On Friday evening after check in and registration, the AMDA hosted a reception “Hoe Down” at...